Who was studied?
One patient with nasopharyngeal carcinoma and multiple bone metastases.
What does the publication report?
PFS of 16 months and OS exceeding 35 months were reported.
Safety findings
No grade 2 or higher treatment-related adverse events were reported.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Denosumab combined with immunotherapy, radiotherapy, and granulocyte-macrophage colony-stimulating factor for the treatment of metastatic nasopharyngeal carcinoma: A case report · DOI: 10.5306/wjco.v16.i2.95642 · PMID: 39995562
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.